Amgen Inc. reports $10.37 billion revenue for quarter ended September 30, 2026, up 8.5%
Amgen Inc. reported revenue of $10.37 billion for the quarter ended September 30, 2026, an increase of 8.5% from the same quarter a year earlier ($9.56 billion).
For the same period it posted net income of $3.86 billion, up 20.1%, or $7.08 per diluted share (5.93 a year earlier).
That is a net margin of 37.3%.
On Sanad's AAOIFI Standard 21 screen, Amgen Inc. is currently compliant: interest-bearing debt is 21.8% of market capitalisation (limit 30%), and impure income is 1.1% of revenue (limit 5%).
Is Amgen Inc. halal?
See the full AAOIFI screening of Amgen Inc.
See the full AAOIFI screening of Amgen Inc.
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.